In the treatment setting, to overcome de novo and acquired resistance of ER-positive breast cancers to anti-estrogen therapy, it is common practice to add CDK4/6 inhibitors (such as palbociclib, ribociclib, and abemaciclib) to anti-estrogen therapy for the treatment of early and late stage breast cancers. This evidence concerns the gene CDK4 and breast carcinoma.